also showing significant reduction in implantation rate (Friedler et al., 1999) . To date, the i.m. route remains the most A polysyloxane vaginal ring containing 1 g of natural widely used form of progesterone replacement. Although i.m. progesterone was developed as luteal supplementation for progesterone has been proved to be effective as luteal support, women treated with IVF-embryo transfer and for agonadal its rapid clearance from circulation requires daily injections women participating in an oocyte donation programme.
for~30 days in IVF-embryo transfer and 100 days in oocyte The ring provides continuous release of progesterone donation. In the past few years, micronized progesterone (10-20 nmol/l) for 90 days. The efficacy of this form formulated in capsules has been used to release the hormone of progesterone supplementation was evaluated in two through the vagina. This delivery system has been successful multicentre prospective randomized trials. IVF-embryo in the preparation of the endometrium for implantation. The transfer trial: After oocyte aspiration, 505 women were dose required is~600-800 mg per day, requiring the insertion randomly allocated to progesterone supplementation with of progesterone tablets in the vagina at least twice a day.
vaginal ring or i.m. progesterone (50 mg/day). The clinical
In regular IVF, the vaginal route has been compared with pregnancy rate was 36.6% in both groups. Implantation parenteral administration; both exhibit similar pregnancy and rate was 15.9% in the vaginal ring and 16.0% in i.m. implantation rates. However, a significant decrease in first progesterone. Oocyte donation trial: After endometrial trimester abortion was observed in women using the vaginal proliferation with micronized oestradiol, 153 women were route (Smitz et al., 1992) . A similar study (Perino et al. 1997 ) allocated to progesterone replacement with a vaginal ring was conducted in 250 patients showing a significantly higher or i.m. progesterone (100 mg/day). Clinical pregnancy rate percentage of pregnancies in women using i.m. progesterone was 39.8 and 28.6% respectively. Implantation rate was compared with micronized progesterone administered via significantly higher with the vaginal ring compared with vagina. In the last 3 years, a progesterone gel has also been i.m. progesterone (19.9 and 11.6% respectively, P ⍧ 0.006).
successfully used, exhibiting similar pregnancy and delivery The vaginal ring is a novel development which provides rates when compared with orally administered micronized continuous release of progesterone for 90 days. In IVFprogesterone (Pouly et al., 1996) . A similar effect was reported embryo transfer, its effectiveness is similar to daily i.m. when comparing the gel with i.m. progesterone (Gibbons injections. In oocyte donation the ring provides a progesta et al., 1998) . tive milieu which improves the implantation rate and
In recent years, a polysyloxane vaginal ring with an external eliminates the discomfort of daily i.m. injections.
diameter of 60 mm and a cross-section of 9 mm was developed Key words: IVF/oocyte donation/progesterone supplementawith the aim of delivering natural progesterone continuously tion/vaginal ring (Jackanicz, 1983 ). This delivery system, which proved to be effective as a contraceptive for lactating women (Massai et al.,1999) , was later re-formulated and used as luteal Introduction supplementation for women participating in (IVF-embryo transfer), and as the only source of progesterone in functionally Exogenous progesterone supplementation has been well established in the treatment of ovulatory dysfunction as well agonadal women participating in oocyte donation. This vaginal ring contains 1 g of natural progesterone and its in-vitro release as in standard IVF-embryo transfer (Soliman et al., 1994) . Furthermore, exogenous progesterone is mandatory as part is 10 mg/day. When placed in the vagina, it provides continuous release of progesterone for as long as 90 days. In a previous of hormonal replacement therapy (HRT) in agonadal women subjected to IVF-embryo transfer after oocyte donation.
study (Zegers-Hochschild et al., 1996) , progesterone concentration in peripheral circulation and endometrial histology was Natural progesterone can be administered orally; however, due (1996) . Values correspond to mean Ϯ SD. similar to the luteal phase of a normal menstrual cycle, except for an advancement in stromal oedema and perivascular
Oocyte donation trial
decidual reaction (Zegers-Hochschild et al., 1996) .
A total of 153 patients with either premature ovarian failure or
The objective of this study was to evaluate the efficacy in repeated failure to respond to ovarian stimulation were subjected to the establishment and maintenance of pregnancy of this vaginal HRT for oocyte donation. Endometrial proliferation was induced with ring when compared with daily i.m. injections of progesterone a fixed oral dose of micronized oestradiol-17β, (4 to 6 mg/day). On in women treated with IVF-embryo transfer and oocyte the day of follicular aspiration in the oocyte donors, recipients were donation.
allocated either to i.m. progesterone, 100 mg/day (n ϭ 70) or to a vaginal ring containing 1 g of natural progesterone (n ϭ 83). Oral concentration of oestradiol was maintained at a fixed dose throughout
Materials and methods
the treatment period. If pregnancy was documented (12 days after This is a prospective randomized study conducted in the Red embryo transfer), the vaginal ring was replaced by a new ring Latinoamericana de Reproducción Asistida. It included three affiliated containing 2 g of progesterone which was left in the vagina for 7 weeks. centres located in Santiago, Chile; Bogotá, Colombia and Sao Paulo, After proper consent, fresh oocytes were donated by women under Brazil. In all centres, patients were recruited among those participating 35 years of age who were simultaneously participating in an IVFin either IVF-embryo transfer or intracytoplasmic sperm injection embryo transfer programme. Consent forms were also signed by (ICSI). Inclusion criteria included all diagnostic categories irrespective oocyte recipients. of the age of female partners. Patients with premature ovarian failure For both trials, comparisons were performed on the clinical or lack of response to ovarian stimulation, were recruited for the pregnancy and live birth delivery rates after embryo transfer and oocyte donation programme, after being adequately informed and implantation rates (number of gestational sacs/ number of embryos with appropriate consent provided to the principal investigator or a transferred) according to the age of the female partner. Statistical designated professional. Each centre used simple randomization tables.
analysis used χ 2 and Fisher tests.
IVF-embryo transfer trial

Results
A total of 505 patients participated in this study. All patients were subjected to ovarian stimulation, which included daily s.c. injections
IVF-embryo transfer trial
of leuprolide acetate starting in the luteal phase of the previous cycle,
In all, 243 patients were included in the vaginal ring group or after discontinuing oral contraceptives. The time of exposure to and 262 in the injectable group. Age distribution and the mean the agonist prior to ovarian stimulation varied between patients, depending on clinical judgement and the need to coordinate dates of number of embryos transferred in each group showed no embryo transfer. In 33% of these women, endometrial bleeding 
Discussion
The polysyloxane vaginal ring is a novel development that significant difference. The median age of the female partner in both groups was 34 years (Table I) .
provides continuous release of natural progesterone for 90 days. Because of its flexibility, a professional or the patient Overall, the clinical pregnancy and implantation rates were similar in women using either vaginal ring or i.m. progesterone may easily place it in the vagina. In oocyte donation, where the source of oocytes is more homogenous (donated by (36.6, 15.9%; and 36.6, 16.0% respectively). Furthermore, implantation rates within pregnant patients were also similar women Ͻ35 years and good responders), the quality of the endometrium can be better isolated as an independent variable. in both groups (41.4% and 41.2% respectively). Multiple pregnancy rate in the vaginal ring was 42.0% (22.7% twins, In these cases, the implantation rate was significantly higher in vaginal ring users (Table V ; P ϭ 0.006). Although not 19.3% triplets or more), and 41.1% (24.2% twins, 16.9% triplets or more) in women using i.m. progesterone (Table II) . statistically significant, the implantation rate in a subgroup of only pregnant patients was also higher in vaginal ring users When grouping the clinical pregnancy rate and implantation rates according to the age of the female partner, differences (46.3%) compared with 39.4% in women using i.m. progesterone. Similarly, when analysing implantation rates in a in these markers were not significant. Only patients with complete information have been included in this analysis (221 group of oocyte recipients whose donors had conceived during a simultaneous IVF cycle, the implantation rate was also patients using vaginal ring and 238 using i.m. progesterone) (Table III) .
higher in women using vaginal ring 29.9% (23/77) compared with 19.7% (12/61) in women using i.m. progesterone. These The outcome of clinical pregnancies is reported in Table  IV . No differences were found in the rate of ectopic pregnancies, clinical studies strongly support the finding that when progesterone is released continuously via a vaginal ring, doses as clinical abortions and deliveries with one or more live births. low as 10 mg/day allow for embryo implantation and the Oocyte donation trial continuation of pregnancy. It has been well established that when progesterone is The age (mean Ϯ SD) of recipients using vaginal ring and i.m. progesterone was 39.2 Ϯ 5.2 and 38 Ϯ 4.5, respectively. released from the vagina, the concentration reached in endometrial tissue is far greater than when the hormone is A mean of 3.4 and 3.5 fresh embryos were transferred in the vaginal ring and injectable groups, respectively. administered i.m. (Miles et al., 1994) . In women treated with oocyte donation, exogenous progesterone is the only source Overall results are provided in Table V . The clinical pregnancy rate was not significantly higher in women using vaginal of the hormone. When using the ring, its concentration in peripheral circulation (10-20 nmol/l) is much lower than the ring over i.m. progesterone, (39.8 and 28.6% respectively). However, the implantation rate was significantly higher in concentration reached after 100 mg of i.m. progesterone (Ͼ80 nmol/l) or progesterone concentration of 30-40 nmol/l patients using vaginal ring, 19.9% compared to 11.6% for i.m. progesterone (P ϭ 0.006). When donors achieved a pregnancy, found in the mid luteal phase of spontaneous conception cycles (Zegers-Hochschild, 1988) . When the vaginal route is used to implantation rate in their simultaneous recipients was 29.9% (23/77) in vaginal ring compared to 19.7% (12/61) in i.m. deliver progesterone, measurement of circulatory concentrations is therefore quite meaningless. This study supports the progesterone. This difference did not reach statistical significance, probably due to the small number of embryos transconcept of a 'first uterine pass effect' (Fanchin et al., 1997) . Furthermore, this study demonstrates that when progesterone ferred in each group (23 pairs of patients). Similarly to the IVF-embryo transfer trial, multiple pregnancy rates were as is delivered in the vagina, circulatory concentrations do not have to mimic the hormonal concentration found in normal high in vaginal ring users as in i.m. progesterone (42.4 and 41.1% respectively). ovulatory cycles. In fact, much less is required to achieve endometrial maturation. The mechanisms by which proThe outcome of clinical pregnancies is reported in Table VI . None of the patients receiving HRT for oocyte donation had gesterone released in the vagina reaches the uterine cavity in higher concentrations than peripheral circulation has been uterine bleeding during their medication, irrespective of the presence or absence of pregnancy. In contrast,~30% of IVF thoroughly reviewed (Cicinelli and de Ziegler, 1999) . Progesterone concentration measured in the uterine vein in women had vaginal bleeding or at least 1 or 2 days of intermittent brownish discharge that started 8-12 days after three women undergoing hysterectomy was three to seven times ents. None of these pregnant patients exposed to the ring containing 2 g had uterine bleeding during their gestation. first value and doubling time of HCG was normal, the presence of vaginal spotting did not seem to interfere with the outcome a Significantly different from the implantation rate in patients using i.m. progesterone (P ϭ 0.006).
of pregnancy. Some doctors, when exposed to vaginal spotting in the presence of positive HCG, increased progesterone either by adding i.m. progesterone, or changing to a ring containing study to elucidate how to treat these cases or whether other forms or doses of hormonal supplementation are required to avoid bleeding. higher than peripheral circulation after 24-36 h of exposure to
The mechanism of uterine bleeding in IVF patients using the vaginal ring containing 1 g. The ratio of progesterone in the ring is not well understood. Bleeding does not take uterine vein/antecubital vein was 67.1/22.6, 90.5/12.4 and place when oestradiol or the oestradiol/progesterone ratio is 65.0/9.5 nmol/l. In two other cases where surgery was indicated maintained constant, as in oocyte donation cycles, except in because of large fibroids in the isthmus region and occupying very few cases when the ring containing 1 g was maintained part of the vagina, progesterone concentrations in the uterine after day 12 of embryo transfer. In these cases, increasing and antecubital veins were not different (32.2/27.5 and vaginal progesterone immediately stopped bleeding. Perhaps 10.9/10.6 nmol/l).
occasional bleedings associated with IVF are related to oscillaIn oocyte recipients, once pregnancy was documented; the tions in endogenous oestradiol or in the local ratio between ring containing 1 g was replaced with a new ring containing oestradiol and progesterone rather than progesterone concentra-2 g of progesterone. This decision was made after some initial cases (not included in this report) experienced uterine bleeding tion alone. On the other hand it has been well documented that
